{"entity":{"id":"nct05491226","kind":"trial","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","aka":[],"tldr":"A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, now recruiting.","summary":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation is a phase 2, interventional study registered as NCT05491226 by Stephen Shiao, with a registry enrolment figure of 35 participants, started 2023-11-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: Pembrolizumab; Radiation Therapy; Axatilimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: \"* Female patients diagnosed with high-risk triple negative breast cancer (TNBC) with intent for neoadjuvant therapy\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05491226","url":"https://clinicaltrials.gov/study/NCT05491226"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05491226","phase":"2","setting":"IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","sponsor":"Stephen Shiao","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05491226/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}